(Q36495584)

14 August 2017

1 reference

title

Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia (English)

1 reference

14 August 2017

1 reference

schizophrenic psychology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1674881

26 October 2022

author name string

D. E. Casey

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1674881

26 October 2022

language of work or name

English

0 references

publication date

1 March 1991

1 reference

full work available at URL

14 August 2017

https://api.elsevier.com/content/article/PII:092099649190029Q?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

https://api.elsevier.com/content/article/PII:092099649190029Q?httpAccept=text/plain

26 October 2022

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

26 October 2022

published in

Schizophrenia Research

1 reference

14 August 2017

volume

4

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

109-120

1 reference

Neuroleptic-induced akathisia: a review

14 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

A survey of drug-induced extrapyramidal reactions

26 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

26 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Tardive dyskinesia: a 3-year follow-up study

26 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Akathisia variants and tardive dyskinesia

26 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs

26 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Behavioral effects of long-term neuroleptic treatment in Cebus monkeys

26 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Pharmacological characterization of tardive dyskinesia

26 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Tardive dyskinesia as a life-threatening illness

26 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Neuroleptic-induced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment

26 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

On the supersensitivity of dopamine receptors, induced by neuroleptics

26 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Changes in dopamine-mediated behaviour during one year's neuroleptic administration

26 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

NEUROLOGICAL SYMPTOMS IN PHARMACOTHERAPY OF PSYCHOSES

26 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Clinical forms of severe tardive dyskinesia

26 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Seven-year follow-up of tardive dyskinesia in Hungarian outpatients.

26 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Dystonic reactions following neuroleptics: Time Course and proposed mechanisms

26 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

26 October 2022

Tardive dyskinesia

35

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia

26 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Haloperidol-induced tardive dyskinesia in monkeys

26 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects

26 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Therapeutic strategies against tardive dyskinesia. Two decades of experience

26 October 2022

41

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Tardive dyskinesia--reversible and persistent

26 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

26 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Initial Anticholinergic Prophylaxis for Neuroleptic-Induced Extrapyramidal Syndromes

26 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

An experimental model of tardive dyskinesia

26 October 2022

50

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Propranolol in the treatment of neuroleptic-induced akathisia

26 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Tardive dyskinesia: are first signs reversible?

26 October 2022

52

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats

26 October 2022

53

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects

26 October 2022

54

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects

26 October 2022

57

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Tardive dyskinesia in the aged. Duration of treatment relationships.

26 October 2022

61

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Acute extrapyramidal side effects: Serum levels of neuroleptics and anticholinergics

26 October 2022

62

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

26 October 2022

64

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

The rabbit syndrome. A peculiar extrapyramidal reaction.

26 October 2022

65

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment

26 October 2022

67

1 reference

https://api.crossref.org/works/10.1016/0920-9964(91)90029-Q

26 October 2022

Identifiers

1 reference

14 August 2017

1 reference